The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie (Inst); Novartis (Inst); Yakult Pharmaceutical (Inst)
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Lilly; Mediscience Planning; MSD; Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst)
Other Relationship - NCCN
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Lilly; Merck; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; GlaxoSmithKline; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; loxo; Merck; Taiho Pharmaceutical; Takeda; Zymeworks
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical
 
Sunnie Kim
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Merck
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; Astellas Pharma; Beigene; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER; Zymeworks
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma; Lilly Japan
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Kohei Shitara
No Relationships to Disclose
 
Ahsan Arozullah
Employment - Astellas Pharma
 
Jung Wook Park
Employment - Astellas Pharma
 
Jeffrey J. Raizer
Employment - Astellas Pharma
Stock and Other Ownership Interests - Agenus; Cancer Action Now; Celldex; Exicure
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Rui-hua Xu
No Relationships to Disclose